PA
CX icon

PharVision Advisers’s Cemex CX Stock Holding History

PharVision Advisers’s Portfolio CX Stock Details CX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,901
Closed -$275K – 243
2025
Q4 		$275K Buy
23,901
+11,165
+88% +$115K 0.14% 330
2025
Q3 		$114K Buy
+12,736
New +$109K 0.06% 611

Other funds holding CX

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IUHSA
Itau Unibanco Holding S.A. Sao Paulo, Brazil $5.27B AUM 41.17% 1-Year Est. Return

PharVision Advisers's CX Position: Q1 2026 in Review

PharVision Advisers sold out of Cemex (CX) in Q1 2026, closing a stake of 23,901 shares — an estimated $275K sold.

PharVision Advisers first reported a position in CX in Q3 2025 and held it in 2 quarters. The position peaked at $275K in Q4 2025. 312 funds tracked by Wall St. Rank hold CX as of Q1 2026.

  • PharVision Advisers reported no remaining Cemex position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 23,901 Cemex shares in Q1 2026, an estimated $275K.
  • PharVision Advisers first reported a position in Cemex in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Cemex position peaked at $275K in Q4 2025.
  • 312 funds tracked by Wall St. Rank held Cemex as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.